Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

186.26 -2.61 (-1.38%)
Official Closing Price Updated: 7:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
President Trump's Tariffs Have Arrived. 3 Things to Do to Protect Your Portfolio.
Via The Motley Fool
Topics Economy Government Stocks
Sit Out Market Drama With These 3 Dividend Funds
 
Via Benzinga
Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study
Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients with no new safety concerns. 
Via Benzinga
Trump's Tariff Exemptions Include Semiconductors, Pharmaceuticals, Oil And More
President Donald Trump on Wednesday announced a slew of tougher-than-anticipated tariffs, but there are some notable exemptions to the steep levies. Here's a look at which products and sectors are... 
Via Benzinga
Topics Government World Trade
Man With $30K To Deploy Wants Dividends For Life – 'Even If It's Just Enough To Pay For A Yearly Vacation Here Or There,' Reddit Reacts
For many investors, dividend-focused stocks and funds provide a way to generate passive income, whether to supplement retirement, cover day-to-day 
Via Benzinga
Topics Retirement
Worried About the Economy? 2 No-Brainer Buys to Shield Your Portfolio.
Via The Motley Fool
Topics Earnings Economy Government
What 13 Analyst Ratings Have To Say About Johnson & Johnson
 
Via Benzinga
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended
Shares of Johnson & Johnson (JNJ) sold off on news regarding a dilution of its earnings. The selloff ended when it reach support. 
Via Benzinga
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership
From Johnson & Johnson
Via Business Wire
J&J Retail Traders Unfazed By Court Rejecting 3rd Talc Settlement, But Analyst Sees Stock Pullback Risk
According to Bloomberg, a monthly prescription of Zepbound via Hims' platform would cost $1,899 — $800 more than Lilly's list price for the drug. 
Via Stocktwits
Topics Bankruptcy Lawsuit
Newsmax, Waton Financial, Johnson & Johnson, Hims & Hers Health, Tesla: Why These 5 Stocks Are On Investors' Radars Today
U.S. stocks closed higher on Tuesday, with the Nasdaq Composite climbing 0.9% to 17,449.89. The S&P 500 added nearly 0.4%, finishing at 5,633.07. 
Via Benzinga
Topics Stocks
Uncover the latest developments among S&P500 stocks in today's session.
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Stock Is Tumbling Tuesday: What Going On?
Johnson & Johnson Inc. (NYSE: JNJ) shares are trading lower Tuesday after a U.S. bankruptcy court in Texas rejected subsidiary Red River Talc's request to approve its prepackaged bankruptcy plan. 
Via Benzinga
Topics Bankruptcy
Why Johnson & Johnson Stock Is Sinking Today
Via The Motley Fool
Topics Bankruptcy Lawsuit Stocks
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday. 
Via Chartmill
Stocks Edge Higher Despite Trade, Economic Jitters
Stocks are modestly higher Tuesday afternoon, as Wall Street shakes off a sluggish open amid a new wave of economic data. 
Via Talk Markets
Topics Stocks / Equities
Wall Street Inches Up Ahead Of Tariff Day: What's Driving Markets Tuesday?
Following the worst quarterly performance for U.S. stocks in over two years, caution dominated Wall Street as investors awaited details on the tariff plans expected from the Trump administration on... 
Via Benzinga
Topics Government World Trade
These S&P500 stocks are gapping in today's session
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Tuesday. Stay informed about the latest market trends. 
Via Chartmill
Why Johnson & Johnson (JNJ) Shares Are Falling Today
Shares of multinational healthcare company Johnson & Johnson (NYSE:JNJ) fell 5.6% in the morning session after a judge in Texas rejected the company's third attempt to use bankruptcy as a legal shield... 
Via StockStory
Topics Bankruptcy Lawsuit
US Manufacturing Slips Into Contraction As Tariff-Driven Costs Hit Near 3-Year High
The brief revival in U.S. factory activity vanished in March as input prices shot up at the fastest pace since mid-2022, raising red flags about eroding profit margins, cost pass-through risks and... 
Via Benzinga
These S&P500 stocks are moving in today's pre-market session
Pre-market stock analysis of S&P500 stocks on 2025-04-01: top gainers and losers in today's session. 
Via Chartmill
J&J Dives After Judge Tosses Out $10 Billion Talc-Based Bankruptcy Plan
The company says it will return to the civil court system to handle tens of thousands of claims its talc-based products caused cancer. 
Via Investor's Business Daily
Topics Bankruptcy Lawsuit
US Judge Rejects Another Johnson & Johnson Attempt To Use Bankruptcy For Talc Cancer Claims
Johnson & Johnson will fight talc lawsuits in court after its subsidiary's bankruptcy plan was denied, reversing $7 billion in legal reserves. 
Via Benzinga
Topics Bankruptcy Lawsuit
Federal Judge Rejects Johnson & Johnson Bankruptcy Strategy, Paving Way for Talc Victims to Seek Justice in Trial Courts
From Beasley Allen Law Firm
Via Business Wire
2 Value Stocks I'm Buying Right Now
Via The Motley Fool
Topics Economy
Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims
From Johnson & Johnson
Via Business Wire
Value Stocks Gain Ground As Inflation, Recession Fears Grow: 4 ETFs To Capitalize On The Trend
Value stocks are outperforming flashy growth rivals due to market uncertainty, making value-based ETFs a good bet for steady income and diversification. 
Via Benzinga
Topics ETFs Economy
1 Healthcare Stock to Target This Week and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Is Hims & Hers Stock Too Cheap to Pass Up?
This high-growth stock may be cheaper than you think. 
Via The Motley Fool
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.